• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors

    10/24/22 9:00:00 AM ET
    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto & Home Supply Stores
    Consumer Discretionary
    Get the next $ELAN alert in real time by email

    TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors.

    Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops polymers that eliminate the need of refrigeration for vaccines and therapeutics.

    Ms. Liu serves on the Board of Directors of CarParts.com (NASDAQ:PRTS), a leading online provider of automotive parts and accessories, and served on the Board of Directors of Kindred Biosciences (NASDAQ:KIN), a leading biopharmaceutical company for pets, until it was acquired by Elanco Animal Health (NYSE:ELAN). She serves on the Board of Advisors for Covington Capital Management and is a Partner at XFactor Ventures, a leading investor in women-founded startups. Ms. Liu was named one of Forbes 30 Under 30 (in 2016) and Fortune's 10 Most Promising Women Entrepreneurs (in 2015).

    "For the past 18 months, we have benefited from Nanxi's advice and guidance as a member of our Advisory Board, and we are pleased to now welcome her as a new member of the Board of Directors," said Joseph R. Shaposhnik, TCW Special Purpose Acquisition Corp. Chairman and CEO. "She is a highly successful technology entrepreneur and brings a unique perspective to the leaders of businesses and our impressive team of advisors and directors."

    TCW Special Purpose Acquisition Corp. intends to identify, merge with and take public a durable and predictable business well positioned to deliver superior revenue growth. Its management is associated with TCW's New America Premier business unit, which was established by Mr. Shaposhnik in 2015.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities.

    About TCW Special Purpose Acquisition Corp.

    TCW Special Purpose Acquisition Corp. (the "Company"), a Delaware corporation, is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with a private company. The Company is sponsored by The TCW Group, Inc., a leading global investment management firm with approximately $220 billion of assets under management. For more information please visit www.tcwspac.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221024005377/en/

    Get the next $ELAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAN
    $PRTS
    $TSPQ
    $KIN

    CompanyDatePrice TargetRatingAnalyst
    Elanco Animal Health Incorporated
    $ELAN
    12/9/2025$30.00Overweight
    Barclays
    Elanco Animal Health Incorporated
    $ELAN
    11/21/2025$27.00Overweight
    KeyBanc Capital Markets
    Elanco Animal Health Incorporated
    $ELAN
    11/19/2025$25.00Hold → Buy
    Argus
    Elanco Animal Health Incorporated
    $ELAN
    10/7/2025$24.00Neutral → Overweight
    Analyst
    Elanco Animal Health Incorporated
    $ELAN
    7/17/2025$18.00Market Perform → Outperform
    Leerink Partners
    Elanco Animal Health Incorporated
    $ELAN
    6/26/2025Mkt Perform → Outperform
    William Blair
    CarParts.com Inc.
    $PRTS
    3/6/2025$3.00Hold → Buy
    Craig Hallum
    Elanco Animal Health Incorporated
    $ELAN
    12/9/2024$18.00Buy
    UBS
    More analyst ratings

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $478,496 worth of shares (22,000 units at $21.75) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:41:24 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Modi Rajeev A. bought $95,985 worth of shares (4,500 units at $21.33), increasing direct ownership by 4% to 123,082 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:43:23 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs

    Conditional Approval Marks Elanco's Third New World Screwworm Treatment Option for Companion Animals, Providing Multiple Treatment Solutions Prior to Fly Being Detected in the U.S. FDA's Conditional Approval of Credelio Quattro-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first for companion animals against New World screwwormAction follows previous Emergency Use Authorizations granted by the FDA for Credelio™ (lotilaner) and Credelio™ CAT (lotilaner) to treat New World screwworm in dogs and cats, respectivelyCredelio Quattro/Credelio Quattro-CA1 provides the broadest parasite coverage of its kind* - covering seven types of parasites including ticks, fleas,

    12/18/25 8:43:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Investor Day Defines New Era as Sustainable Growth Company

    Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and low double-digit adjusted EPS growth, all starting in 2026. Expects further net leverage ratio improvement to <3x in 2027, with a long-term target of 2.0x to 2.5x.Expects innovation revenue contribution of approximately $1.1 billion in 2026, with aims to double revenue from 'Big 6' blockbuster potential products by 2028.Discusses 10+ major innovation products in development phase with 5-6 blockbuster-potential approvals expected between 2026 and 2031. Two in-house technology development platforms

    12/9/25 7:40:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco executive appointed as Neurizon's Board Observer

    MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited ((ASX: NUZ &, NUZOA, OTCQB:NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE:ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative. The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. The appointment follo

    11/26/25 6:15:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    SEC Filings

    View All

    CarParts.com Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Shareholder Director Nominations

    8-K - CarParts.com, Inc. (0001378950) (Filer)

    12/15/25 4:11:38 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    Elanco Animal Health Incorporated filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Elanco Animal Health Inc (0001739104) (Filer)

    12/9/25 7:45:37 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by CarParts.com Inc.

    144 - CarParts.com, Inc. (0001378950) (Subject)

    11/26/25 4:25:15 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:41:51 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:41:08 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Elanco Animal Health with a new price target

    Barclays initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $30.00

    12/9/25 8:46:01 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KeyBanc Capital Markets initiated coverage on Elanco Animal Health with a new price target

    KeyBanc Capital Markets initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $27.00

    11/21/25 8:08:36 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health upgraded by Argus with a new price target

    Argus upgraded Elanco Animal Health from Hold to Buy and set a new price target of $25.00

    11/19/25 9:01:05 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Financials

    Live finance-specific insights

    View All

    Elanco Investor Day Defines New Era as Sustainable Growth Company

    Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and low double-digit adjusted EPS growth, all starting in 2026. Expects further net leverage ratio improvement to <3x in 2027, with a long-term target of 2.0x to 2.5x.Expects innovation revenue contribution of approximately $1.1 billion in 2026, with aims to double revenue from 'Big 6' blockbuster potential products by 2028.Discusses 10+ major innovation products in development phase with 5-6 blockbuster-potential approvals expected between 2026 and 2031. Two in-house technology development platforms

    12/9/25 7:40:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CarParts.com Reports Third Quarter 2025 Results

    TORRANCE, Calif., Nov. 10, 2025 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ:PRTS), a leading eCommerce provider of automotive parts and accessories, and a premier destination for vehicle repair and maintenance needs, is reporting results for the third quarter ended September 27, 2025.  Third Quarter 2025 Summary vs. Year-Ago Quarter Net sales decreased 12% to $127.8 million.Gross profit of $42.3 million vs. $51.0 million, with gross margin of 33.1%.Net loss was ($10.9) million, or ($0.19) per share, compared to a net loss of ($10.0) million, or ($0.17) per share.Adjusted EBITDA

    11/10/25 4:01:00 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    CarParts.com Announces Date Change for its Third Quarter 2025 Conference Call

    LOS ANGELES, Oct. 31, 2025 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ:PRTS) today announced that the company has rescheduled the date of its third quarter 2025 conference call. The company will now have the call on Monday, November 10, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). The results will be reported in a press release prior to the call. CarParts.com, Inc. CEO David Meniane and CFO Ryan Lockwood will host the conference call live via an audio webcast. The live webcast of the event can be accessed at www.carparts.com/investor/news-events. A replay of the web

    10/31/25 4:01:00 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Leadership Updates

    Live Leadership Updates

    View All

    Elanco executive appointed as Neurizon's Board Observer

    MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited ((ASX: NUZ &, NUZOA, OTCQB:NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE:ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative. The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. The appointment follo

    11/26/25 6:15:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    Banks
    Finance
    Savings Institutions
    Biotechnology: Pharmaceutical Preparations

    Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

    The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are

    6/5/25 7:45:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CarParts.com Inc.

    SC 13G/A - CarParts.com, Inc. (0001378950) (Subject)

    11/12/24 1:35:28 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by CarParts.com Inc.

    SC 13G/A - CarParts.com, Inc. (0001378950) (Subject)

    11/4/24 10:24:21 AM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by CarParts.com Inc.

    SC 13G/A - CarParts.com, Inc. (0001378950) (Subject)

    9/10/24 12:09:00 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary